Home/Filings/4/0001062993-23-018279
4//SEC Filing

Menold Daniel 4

Accession 0001062993-23-018279

CIK 0001042074other

Filed

Sep 18, 8:00 PM ET

Accepted

Sep 19, 5:25 PM ET

Size

14.2 KB

Accession

0001062993-23-018279

Insider Transaction Report

Form 4
Period: 2023-09-15
Menold Daniel
Vice President, Finance
Transactions
  • Exercise/Conversion

    Common Stock

    2023-09-15$1.82/sh+1,545$2,8121,545 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2023-09-151,5450 total
    Exercise: $1.82Exp: 2026-07-24Common Stock (1,545 underlying)
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2023-09-1515,0000 total
    Exercise: $1.72Exp: 2027-01-18Common Stock (15,000 underlying)
  • Sale

    Common Stock

    2023-09-15$16.87/sh0$00 total
  • Exercise/Conversion

    Common Stock

    2023-09-15$1.72/sh+15,000$25,80015,000 total
  • Sale

    Common Stock

    2023-09-15$16.87/sh0$00 total
Footnotes (4)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.44 to $17.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on July 22, 2017, and the remaining shares vested in equal monthly installments over the next 36 months.
  • [F4]The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in equal monthly installments over the next 36 months.

Issuer

CymaBay Therapeutics, Inc.

CIK 0001042074

Entity typeother

Related Parties

1
  • filerCIK 0001705745

Filing Metadata

Form type
4
Filed
Sep 18, 8:00 PM ET
Accepted
Sep 19, 5:25 PM ET
Size
14.2 KB